Market Introduction
The cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are some of the symptoms. Individuals suffering from cardiometabolic syndrome are prone to several other life-threatening diseases such as type 2 diabetes, stroke, coronary artery disease (CAD), cardiovascular disease (CVD), and many others.
Moreover, the increasing prevalence of cardiometabolic diseases is expected to bolster the market growth during the forecast period. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) limits the growth of the North America cardiometabolic diseases market.
The impact of COVID-19 continues to surge, and the resulting burden on medical systems has disrupted economies, healthcare systems, and ongoing clinical trials. The COVID-19 pandemic has also triggered the onset of or exacerbate cardiovascular diseases. Also, the COVID-19 is causing serious mental health issues, and the association between depression and cardiovascular disease has long been reported. As per the Cleveland Clinic, approximately 15% of patients with CVD and up to 20% of patients who have undergone coronary artery bypass graft surgery experience major depression. Even mild depression, such as a depressed mood, can increase the relative risk of coronary artery disease. Restrictive measures taken during the COVID-19 pandemic might have increased depression in patients with cardiovascular diseases. Also, many companies have reported a decline in sales of CVD and diabetes drugs in the US. For instance, in Q4 2020, Sanofi’s global diabetes sales decreased 8.4% due to a continued decline in the average US glargine price and some impact from the COVID-19 environment. Also, cardiovascular products sales decreased 7.1%, partially due to the COVID-19 environment.
Market Overview and Dynamics
The North America cardiometabolic diseases market is projected to reach US$ 43,583.6 million by 2028 from US$ 32,912.1 million in 2021; it is anticipated to grow at a CAGR of 4.1% from 2021 to 2028. The integration of AI is further offering lucrative opportunities for the growth of the worldwide cardiometabolic disease market and is expected to continue supporting this market over the forecast period. In June 2021, The ACC and GE Healthcare collaborated through the support of and participation in ACC's Applied Health Innovation Consortium (AHIC) to build a roadmap for AI and digital technology in cardiology and develop new strategies for improved health outcomes.
Key Market Segments
In terms of type, the cardiovascular disease segment accounted for the largest share of the North America cardiometabolic diseases market in 2020. In terms of treatment, the ACE inhibitors segment accounted for the largest share of the North America cardiometabolic diseases market in 2020. In terms of dosage, the tablet segment accounted for the largest share of the North America cardiometabolic diseases market in 2020. In terms of route of administration, the oral segment accounted for the largest share of the North America cardiometabolic diseases market in 2020. In terms of end user, the hospital segment accounted for the largest share of the North America cardiometabolic diseases market in 2020. Further, based on distribution channel, the hospital pharmacy segment held the largest market share in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the cardiometabolic diseases market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Eli Lilly and Company., Bayer AG, Arrowhead Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc., Cardax, Inc., and Kowa Company, Ltd.
Reasons to Buy Report
- To understand the North America cardiometabolic diseases market landscape and identify market segments that are likely to guarantee a strong return
- To comprehend the ever-changing market landscape and stay ahead in competition
- To efficiently plan merger and acquisition, and partnership deals in the North America cardiometabolic diseases market by identifying segments with the most promising probable sales
- To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
- To obtain market revenue forecast of the North America cardiometabolic diseases market based on various segments for the period 2021–2028
NORTH AMERICA CARDIOMETABOLIC DISEASES MARKET SEGMENTATION
By Type
- Cardiovascular disease (CVD)
- Type 2 diabetes
- Hypertension
- Obesity
By Treatment
- ACE inhibitors
- Diuretics
- Glucophage
- Others
By Dosage
- Tablet
- Injection
By Route of Administration
- Oral
- Intravenous
By End Users
- Hospital
- Clinic
- Homecare setting
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- North America
- US
- Canada
- Mexico
Companies Mentioned
- Eli Lilly and Company.
- Bayer AG
- Arrowhead Pharmaceuticals, Inc
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Cardax, Inc.
- Kowa Company, Ltd.
North America Cardiometabolic Diseases Market Strategic Insights
North America Cardiometabolic DiseasesMarket Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 32,912.1 Million |
| Market Size by 2028 | US$ 43,583.6 Million |
| CAGR (2021 - 2028) | 4.1% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
North America Cardiometabolic Diseases Market Country and Regional Insights
